UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

	Und	er the Securities Exchange Act of 1934	
	TE	RNS PHARMACEUTICALS, INC.	
		(Name of Issuer)	
	COMMON	STOCK, PAR VALUE \$0.0001 PER SH	ARE
		(Title of Class of Securities)	
		880881107	
		(CUSIP Number)	
-		JUNE 20, 2023	
	(Date of e	event which requires filing of this statemer	.t)
Check the appropriate box to des	signate the rule pursuant to wh	nich this Schedule is filed:	
o Rule 13d-1(b)			
☑ Rule 13d-1(c)			
o Rule 13d-1(d)			
		orting person's initial filing on this form wit ulter the disclosures provided in a prior cove	h respect to the subject class of securities, and for any
	ct to the liabilities of that secti		rpose of Section 18 of the Securities Exchange Act of r provisions of the Act (however, see the notes). Page 2 of 10
			-
NAMES OF REPORT Millennium Managem			
CHECK THE APPRO	PRIATE BOX IF A MEMBER	R OF A GROUP	
2 (a) o (b) o			
3 SEC USE ONLY CITIZENSHIP OR PL	ACE OF ORGANIZATION		
4 Delaware			
	SOLE VOTI	NG POWER	
	5 -0-		
NUMBER OF	CHARED V	OTING POWER	

4	Delaware					
			SOLE VOTING POWER -0-			
	NUMBER OF SHARES BENEFICIALLY OWNED BY	6	SHARED VOTING POWER 2,313,370 (See Item 4(a))			
	OWNED BY EACH REPORTING PERSON WITH		SOLE DISPOSITIVE POWER -0-			
	TEROON WITH	8	SHARED DISPOSITIVE POWER 2,313,370 (See Item 4(a))			
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,313,370 (See Item 4(a))					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.1%					

12 TYPE OF REPORTING PERSON
OO

CI ICID N		1			ا م ا	
CUSIP No.	880881107	SCHEDULE 13G	Page [3	of	10
					_	

1	NAMES OF REPORTING PERSONS						
	Millennium Group Management LLC						
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
2	(a) o						
	(b) o						
3	SEC USE ONLY						
	CITIZENSHIP OR PLACE	OF ORG	ANIZATION				
4							
	Delaware						
			SOLE VOTING POWER				
		5					
			-0-				
	NUMBER OF		SHARED VOTING POWER				
	SHARES	6					
	BENEFICIALLY OWNED BY		2,313,370 (See Item 4(a))				
	EACH		SOLE DISPOSITIVE POWER				
	REPORTING	7					
	PERSON WITH		-0-				
	1210011 ((1111		SHARED DISPOSITIVE POWER				
		8					
			2,313,370 (See Item 4(a))				
	AGGREGATE AMOUNT B	ENEFIC	ALLY OWNED BY EACH REPORTING PERSON				
9							
	2,313,370 (See Item 4(a))						
	CHECK BOX IF THE AGG	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
10							
	0						
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
11							
	4.1%	4.1%					
	TYPE OF REPORTING PER	RSON					
12							
	00						

CUSIP No.	880881107	SCHEDULE 13G	Page	4	of	10
-----------	-----------	--------------	------	---	----	----

1	NAMES OF REPORTING PERSONS Israel A. Englander				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) 0 (b) 0				
3	SEC USE ONLY				
4	CITIZENSHIP OR PLACE United States	OF ORG	ANIZATION		
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER -0-		
		6	SHARED VOTING POWER 2,313,370 (See Item 4(a))		
		7	SOLE DISPOSITIVE POWER -0-		
		8	SHARED DISPOSITIVE POWER 2,313,370 (See Item 4(a))		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,313,370 (See Item 4(a))				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.1%				
12	TYPE OF REPORTING PERSON IN				

Item 1.

(a) Name of Issuer:

Terns Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

1065 East Hillsdale Boulevard, Suite 100 Foster City, California 94404

<u>Item 2.</u> (a) <u>Name of Person Filing:</u>

- (b) Address of Principal Business Office:
- (c) Citizenship:

Millennium Management LLC 399 Park Avenue New York, New York 10022 Citizenship: Delaware

Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Citizenship: Delaware

Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Citizenship: United States

(d) <u>Title of Class of Securities</u>:

common stock, par value \$0.0001 per share ("Common Stock")

(e) CUSIP Number:

880881107

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

- (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
- (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

CUSIP No.	880881107	SCHEDULE 13G	Page	6	of	10
-----------	-----------	--------------	------	---	----	----

- (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned:

See response to Item 9 on each cover page.

After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on June 20, 2023, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.

(b) Percent of Class:

See response to Item 11 on each cover page.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

See response to Item 5 on each cover page.

Page [

of

1

(ii) Shared power to vote or to direct the vote

See response to Item 6 on each cover page.

(iii) Sole power to dispose or to direct the disposition of

See response to Item 7 on each cover page.

(iv) Shared power to dispose or to direct the disposition of

See response to Item 8 on each cover page.

The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following b.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group

See Exhibit I.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 880881107 SCHEDULE 13G Page 8 of 10

Exhibits:

Exhibit I: Joint Filing Agreement, dated as of June 26, 2023, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

CUSIP No. 880881107 **SCHEDULE 13G** Page 9 of 10

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: June 26, 2023

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

/s/ Israel A. Englander

Israel A. Englander

CUSIP No. 880881107 SCHEDULE 13G Page 10 of

EXHIBIT I

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value \$0.0001 per share, of Terns Pharmaceuticals, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: June 26, 2023

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

/s/ Israel A. Englander

Israel A. Englander